You are here

Award Data

For best search results, use the search terms first and then apply the filters

The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.

Download all award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. A Novel Two-in-One Approach to Administer Surfactant and Provide Airway Support to VLBW Infants

    SBC: BB MEDICAL SURGICAL, INC.            Topic: NICHD

    PROJECT SUMMARY / ABSTRACT Every year, 50,000 very low birth weight (VLBW, andlt;1,500 g) infants are born in the U.S. The use of surfactant dramatically decreases morbidity and mortality due to respiratory distress syndrome (RDS) in VLBW infants. Current standards for surfactant administration require the infant to be intubated, so that surfactant can be delivered to the trachea and lungs. Intuba ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Ultra-sensitive Rapid Diagnostic Test to Support the End-Game of the Global Program to Eliminate Lymphatic Filariasis

    SBC: NANOCOMPOSIX, INC.            Topic: NIAID

    Project SummaryAbstract Lymphatic filariasisLFcaused by the parasitic filarial worm Wuchereria bancroftiis a disfiguring and debilitating neglected tropical disease that affectsmillion people incountriesThrough the World Health Organization sWHOGlobal Program for the Elimination of Lymphatic FilariasisGPELFbillion drug regimens have been distributed via mass drug administrationMDAtomillion people ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Urocortin-2 Gene Transfer for Type 1 Diabetes and Associated LV Dysfunction

    SBC: Renova Therapeutics, Inc.            Topic: NHLBI

    ABSTRACT TypeDiabetes MellitusT DMaffectsmillion patients in US withnew patients annuallyLifespan is shortenedyearsdue to kidney and heart diseaseTight glucose control reduces microvascular complications and adverse cardiovascular eventsInsulin therapy is essential for such patientsbut has shortcomingsaonlyinpatients achieve targeted glucose controlHbA c andltbaggressive insulin therapy increases ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. A microfluidic device for blood analysis in neonates

    SBC: Sersense Inc            Topic: NICHD

    ABSTRACT Premature infants are frequently at risk of infectionjaundice and hypoglycemiaconditions monitored by analysis of blood for c reactive proteinCRPbilirubin and glucose respectivelyTypicallymL of blood is drawn each time an infant is tested with multiple blood draws happening over the course of daysGiven that total blood volume of in premature infants ismLup toof blood volume may be lost du ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Gallium 68 Tilmanocept for PET Imaging of Atherosclerosis Plaques

    SBC: Navidea Biopharmaceuticals, Inc.            Topic: NHLBI

    Myocardial infarctionsMIor heart attacksischemic strokesISand peripheral artery diseasePADtogether considered cardiovascular diseaseCVDare all commonly caused by the same underlying pathologyatherosclerosisMIs and ISs are the leading causes of death and disability worldwideAtherosclerosis is a progressive pathology that develops asymptomatically over the course of many years as inflammatory plaque ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Targeting neurotoxic alpha-synuclein aggregates for Parkinson's disease therapy.

    SBC: Vova Ida, LLC            Topic: 999

    SUMMARYParkinsonandapos s diseasePDis the second most prevalent neurodegenerative disorder after Alzheimerandapos s diseaseADaffecting more thanmillion people in the United StatesBecause age is the major risk factorthe prevalence of both diseases is steadily increasing as our population agesPD belongs to the group of protein misfolding neurodegenerative diseases that are due to the misfolding and ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. A dual histone deacetylase and glycogen synthase kinase 3 beta inhibitor for treating pancreatic adenocarcinoma

    SBC: Avenzoar Pharmaceuticals, Inc.            Topic: 102

    ABSTRACT Pancreatic cancer is a disease with no effective treatmentIt s low five year survival rateestimated at betweenandranks it the fourth highest of cancer related of death in the U Sdespite being the twelfth most common type of cancerEach year in the U Sthere are nearlynew cases and more thandeaths caused by the diseaseBypancreatic cancer is expected to be the second most common cancer relate ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. CIM-MIAS (Cyber Information Management and Mission Impact Analysis System)

    SBC: Modus Operandi, Inc.            Topic: AF18CT002

    The DoD lacks an multi-level security (MLS) cyber information management (CIM) system capable of collecting, sharing and disseminating cyber information containing threats, system vulnerabilities and mission impacts and risks for systems operating at multiple security levels. A system that can securely collect and persist this information from various systems operating at various security levels i ...

    STTR Phase I 2019 Department of DefenseAir Force
  9. Portable Bioprinted Organoids for Physiological Monitoring

    SBC: CFD Research Corporation            Topic: AF19AT002

    hazardous chemicals such as JP8, chromium, and byproducts of led-free frangible ammunition and to hazardous environments. Of the many dangers Airmen face, the hypoxia-like unexplained physiological events pilots face are some of the most dangerous and elusive. Current wearable sensors cannot decouple complex, interdependent in vivo response. We propose to develop (design, fabricate, test, and demo ...

    STTR Phase I 2019 Department of DefenseAir Force
  10. Toolset For Prediction of Carbon-Carbon Aeroshell Properties Based On Constituent Materials And Manufacturing Process Parameters

    SBC: ATA Engineering, Inc.            Topic: AF19AT021

    Carbon-carbon (C-C) composites are used in the fabrication of aeroshells and thermal protection systems (TPS) in hypersonic and atmospheric reentry applications because they maintain their strength at elevated temperatures and have desirable thermal conductivity properties. Although these materials have been used in mission-critical components for decades, the effects of variations in processing m ...

    STTR Phase I 2019 Department of DefenseAir Force
US Flag An Official Website of the United States Government